Prelude Therapeutics Incorporated : June 2021 Corporate Presentation

Corporate Presentation

June 2021

Disclaimer

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic and the sufficiency of our cash and cash equivalents to fund our operations.

Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as ''believe,'' ''may,'' ''will,'' ''potentially,'' ''estimate,'' ''continue,''

''anticipate,'' ''intend,'' ''could,'' ''would,'' ''project,'' ''plan,'' ''expect'' and similar expressions that convey uncertainty of future events or outcomes,

although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).

These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended March 31, 2021.

2

Prelude Therapeutics Vision

Building a patient-focused precision oncology company

Discovery Engine

Powered by scientists with a track record of delivering precision oncology medicines

Clinical Development

Highly selected patient populations & cancers with significant unmet need

Regulatory Strategy

Efficient development path with potential for accelerated regulatory approvals

Commercial Approach

Rapidly advancing potentially high value therapy candidates with a commitment to future patient access, awareness, and support

3

Senior Management & Board of Directors

Experienced. Proven. Focused.

		Parsaclisib
Peggy Scherle, PhD	Andrew Combs, PhD	David Mauro, MD, PhD
Chief Scientific Officer	Executive Vice President	Chief Medical Officer
	and Head of Chemistry

Kris Vaddi, PhD

Founder &

Chief Executive Officer

Founding member

Deborah Morosini, MD, MSW	Christopher Pierce, MBA	Brian Piper, MBA
Executive Vice President	Executive Vice President	Chief Financial Officer
and Chief of Clinical Affairs	and Chief of Business
	Operations

Board of Directors

Paul Friedman, MD

CEO

Former CEO

Mardi Dier

CFO

Former CFO,

CBO

Victor Sandor, MD

Former CMO

David Bonita, MD

General

Partner

Julian C. Baker

Managing Member

Baker Brothers Investments

Kris Vaddi, PhD

Founder &

Chief Executive Officer

4

Prelude Therapeutics Corporate Highlights

4 INDs cleared to date;

3 Clinical stage programs;

3 Preclinical assets

Highly productive target class agnostic discovery engine

Pipeline focused on differentiated and validated targets

Compelling market opportunities across multiple tumor types

Patient-inspired drug development, regulatory, and commercial strategies to address high unmet need

Multiple wholly owned programs with fast-to-market potential

Lead programs, PRT543 & PRT811 (PRMT5) and PRT1419 (MCL1) target clinically validated mechanisms with differentiated product profile

Experienced leadership team with marquee investors and board members

Deeply experienced employee base that has worked on multiple approved targeted agents

5